Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Hematology
•
Pediatric Hematology
•
Benign Hematology
•
Hemophilia
In light of the Haven 7 trial results, what considerations should be made regarding the monitoring and management of potential long-term adverse effects of emicizumab in infants?
Related Questions
How would you manage aplastic anemia refractory to multiple agents?
What experience have you had with familial clustering of polycythemia vera?
How do you approach the work-up for a patient with iron deficiency anemia who is not responding to oral iron therapy?
Can lupus anticoagulant be positive despite a normal aPTT?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
For mild to moderate hemophilia B, do you routinely screen for inhibitors?
For von Willebrand type 2B, do you expect a decline in platelet count over time as vWF increases with age?
How do you counsel patients with acute intermittent porphyria when it comes to fasting for religious reasons?
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
